SecBot SecBot
8-K ·Filed Nov 12, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Impact 5/10
Horizonmonths Processed4d 10h ago SEC0001140361-26-043434
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The FDA alignment on the Danon disease pivotal trial is the most significant catalyst. Monitor enrollment progress toward the mid-2027 dosing completion target and any interim safety/efficacy updates. KRESLADI commercial launch in Q4 2026 will provide the first revenue stream, though initial patient numbers will be small given the ultra-rare indication.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

RCKT drug pipeline →

KRESLADI

● Neutral Named in this 8-K
Impact
Phase
Approved (FDA accelerated approval)
Time to market
Already FDA-approved (March 26, 2026); commercial launch underway
Next catalyst
None dated

What to watchKRESLADI's approval and the $180M PRV sale provide a cash runway into Q2 2028, but the drug is an ultra-orphan gene therapy with a "minimal viable launch", not a major revenue generator. Watch the company's cardiovascular pipeline (RP-A501 for Danon disease, RP-A701 for BAG3 cardiomyopathy) for future catalysts. RCKT carries heavy short interest (~25.5% of float), a squeeze risk if pipeline data hits, but the clinical hold history on RP-A501 adds risk.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$2.30
T+0 close · Nov 12, 2026 · via day close
Latest settled
−6.09%
T+1 · $2.16
Vs SPY
−4.18%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $2.30entry
  2. T+1 · 20h ago −6.09%α −4.18% · $2.16
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rocket Pharmaceuticals reported Q3 2026 financial results: net loss of $49.2 million ($0.43 per share) vs. $50.3 million loss ($0.45) a year ago, roughly in line with the $-0.41 consensus. The key stock-moving news is FDA alignment on the pivotal Phase 2 trial for RP-A501 in Danon disease, with dosing completion expected by mid-2027 and topline results in mid-2028. Cash of $279.4 million plus a $150 million Hercules credit facility extends runway into Q3 2028, with potential extension into 2029.

Key Financial Metrics

EPS
−$0.43
est −$0.41 · -4.9%
Rating
miss

Key Facts

  • FDA alignment on pivotal Phase 2 trial of RP-A501 in Danon disease: 12-patient population, 12-month co-primary endpoints, dosing completion by mid-2027, topline results mid-2028
  • Q3 2026 net loss of $49.2 million ($0.43 per share) vs. $50.3 million loss ($0.45) in Q3 2025
  • Cash, cash equivalents and investments of $279.4 million as of September 30, 2026
  • Hercules Capital credit facility of up to $150 million; $35 million drawn at closing
  • KRESLADI achieved commercial readiness on October 1, 2026; two Qualified Treatment Centers activated
  • Dosing initiated in Phase 1 trial of RP-A701 for BAG3-DCM; EMA orphan designation granted October 20, 2026
  • R&D expenses decreased to $31.2 million from $34.1 million year-over-year
  • 111,386,536 shares outstanding as of September 30, 2026

Financial Impact

Q3 net loss $49.2 million, cash burn rate ~$16.4 million/month; cash runway into Q3 2028 with potential extension via credit facility

cash positionnet lossR&D expenses

Risk Factors

  • Danon disease pivotal trial may fail to meet co-primary endpoints (myocardial LAMP2 expression and LV mass index reduction)
  • KRESLADI commercial revenue may be slow to materialize due to ultra-rare patient population and complex treatment logistics
  • Cash runway depends on operating plan assumptions; additional Hercules draws are subject to conditions and approval
  • Competing gene therapy programs for cardiomyopathies could emerge

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-043434
Document: ef20085455_8k.htm0001140361-26-043434
Document: 0001140361-26-043434-index-headers.html0001140361-26-043434
Document: 0001140361-26-043434-index.html0001140361-26-043434
Document: 0001140361-26-043434.txt0001140361-26-043434
8-K Data (Synthetic)0001140361-26-043434

Track record

21 reports on RCKT

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
  3. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Viewing Entry $2.30 Now $2.16 −6.09% settles Dec 14
  5. Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
  7. Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
  8. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
  9. Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
  10. Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026